At the time of writing, Recursion Pharmaceuticals Inc [RXRX] stock is trading at $4.66, down -0.85%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RXRX shares have gain 10.95% over the last week, with a monthly amount drifted -2.31%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Recursion Pharmaceuticals Inc [NASDAQ: RXRX] stock has seen the most recent analyst activity on December 17, 2025, when JP Morgan upgraded its rating to a Overweight but kept the price target unchanged to $11 for it. On May 22, 2023, Morgan Stanley initiated with a Equal-Weight rating and assigned a price target of $8 on the stock. Needham started tracking the stock assigning a Buy rating and suggested a price target of $17 on March 16, 2023. KeyBanc Capital Markets initiated its recommendation with a Overweight and recommended $20 as its price target on September 16, 2022. BofA Securities downgraded its rating to Neutral for this stock on April 18, 2022, but kept the price target unchanged to $10. In a note dated March 04, 2022, SVB Leerink downgraded an Mkt Perform rating on this stock but restated the target price of $10.
For the past year, the stock price of Recursion Pharmaceuticals Inc fluctuated between $3.79 and $12.36. Currently, Wall Street analysts expect the stock to reach $11 within the next 12 months. Recursion Pharmaceuticals Inc [NASDAQ: RXRX] shares were valued at $4.66 at the most recent close of the market. An investor can expect a potential return of 136.05% based on the average RXRX price forecast.
Analyzing the RXRX fundamentals
According to Recursion Pharmaceuticals Inc [NASDAQ:RXRX], the company’s sales were 43.69M for trailing twelve months, which represents an -80.16% plunge. Gross Profit Margin for this corporation currently stands at -0.94% with Operating Profit Margin at -16.62%, Pretax Profit Margin comes in at -16.44%, and Net Profit Margin reading is -16.44%. To continue investigating profitability, this company’s Return on Assets is posted at -0.51, Equity is -0.73 and Total Capital is -0.58. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Recursion Pharmaceuticals Inc [NASDAQ:RXRX] has a current ratio of 4.60. In addition, the Quick Ratio stands at 4.60 and the Cash Ratio stands at 4.25. Considering the valuation of this stock, the price to sales ratio is 55.99, the price to book ratio is 2.19.
Transactions by insiders
Recent insider trading involved Borgeson Blake, Director, that happened on Jan 06 ’26 when 0.22 million shares were sold. Director, Gibson Christopher completed a deal on Jan 05 ’26 to sell 40000.0 shares. Meanwhile, Director Borgeson Blake bought 0.22 million shares on Jan 06 ’26.
